Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

SBRT Appears to Be Safe, Feasible in Oligometastatic Disease With Multiple Metastases

May 20th 2021

Stereotactic body radiotherapy can safely be used to treat patients with oligometastatic disease with 3 to 4 metastases or 2 metastases in close proximity to each other, according to results from the phase 1 NRG-BR001 trial.

Dr. Ramaswamy on the Potential for Adjuvant CDK4/6 Inhibition in HR+/HER2- Breast Cancer

May 19th 2021

Bhuvaneswari Ramaswamy, MD, discusses the potential utility of CDK4/6 inhibitors in the adjuvant setting for patients with hormone receptor–positive, HER2-negative breast cancer.

Dr. Johnson on Racial Disparities in Outcomes Across Multiple Tumor Types

May 19th 2021

Anita Johnson, MD, FACS, discusses racial disparities in outcomes across multiple tumor types.

Dr. Lower on the Impact of Tucatinib on HER2+ Breast Cancer

May 17th 2021

Elyse Lower, MD, discusses the impact of tucatinib on the treatment of patients with HER2-positive breast cancer.

Enobosarm Induces a 50% CBR in AR+/ER+ Metastatic Breast Cancer That Has Progressed on Palbociclib

May 17th 2021

Enobosarm has been shown to induce a clinical benefit rate of 50% at 24 weeks in evaluable patients with measurable metastatic androgren receptor–positive, estrogen receptor–positive, metastatic breast cancer that has progressed on treatment with palbociclib.

HR+ Breast Cancer: Role of RxPONDER Data in Clinical Practice

May 17th 2021

Lajos Pusztai, MD, PhD, and Priyanka Sharma, MD, share closing thoughts on additional data they hope to see from the RxPONDER trial, and using these data in clinical practice for the treatment of HR+ early breast cancer.

Long-Term Neoadjuvant Study Tests Nivolumab in ER+/HER2- Breast Cancer

May 17th 2021

Investigators are evaluating the addition of nivolumab to standard neoadjuvant therapy in patients with high-risk, estrogen-receptor–positive/ HER2-negative breast cancer to determine whether the PD-1 immune checkpoint inhibitor can improve recurrence rates.

HR+ Breast Cancer: Impact of RxPONDER on Clinical Practice

May 17th 2021

Questions to consider when approaching the treatment of HR+, HER2-breast cancer based on the RxPONDER trial results.

NCCN Guideline Updates for HR+ Operable Breast Cancer

May 17th 2021

Experts in breast cancer comment on NCCN guideline recommendations as they reflect the outcomes of the RxPONDER trial for HR+ early breast cancer.

Pembrolizumab Significantly Improves EFS as Neoadjuvant, Adjuvant Therapy in High-Risk, Early-Stage TNBC

May 13th 2021

Neoadjuvant pembrolizumab in combination with chemotherapy followed by adjuvant pembrolizumab monotherapy resulted in a significant improvement in event-free survival and pathologic complete response vs neoadjuvant chemotherapy alone in patients with high-risk, early-stage triple-negative breast cancer.

Dr. Voorwerk on Rationale for Atezolizumab/Carboplatin in Metastatic Lobular Breast Cancer

May 12th 2021

Leonie Voorwerk, discusses the rationale for examining the combination of atezolizumab plus carboplatin in patients with metastatic lobular breast cancer.

Dr. Hassan on the Mechanism of Action of Talazoparib in TNBC

May 12th 2021

Saima Hassan, MD, PhD, FRCSC, discusses the mechanism of action of talazoparib in triple-negative breast cancer.

Dr. Gatti-Mays on Selecting Between FDA-Approved Assays for PD-L1 Expression in Breast Cancer

May 11th 2021

Margaret E. Gatti-Mays, MD, MPH, FACP, discusses considerations for selecting between FDA-approved companion diagnostic assays for measuring PD-L1 expression in triple-negative breast cancer.

Neratinib Shows Numeric OS Benefit, Trend Toward Improved CNS Outcomes in Early-Stage HER2+ Breast Cancer

May 10th 2021

Although fewer deaths were reported with neratinib in patients with HER2-positive breast cancer treated on the phase 3 ExteNET trial, the agent was not found to result in a significant improvement in overall survival after 8 years of follow-up.

Clinical Benefit With Endocrine Therapy Differs By Risk of Distant Disease Recurrence in Premenopausal ER+ Breast Cancer

May 10th 2021

Stratification by the molecular 70-gene risk prediction signature revealed that patients with estrogen receptor–positive breast cancer who are low risk for disease recurrence derive greater benefit from tamoxifen, while those who are high risk have greater benefit from goserelin vs no endocrine therapy.

HR+ Breast Cancer: Practical Implications of RxPONDER

May 10th 2021

The practice-changing results and implications from the RxPONDER trial for early-stage HR+ breast cancer is discussed.

Adjuvant CDK4/6 Inhibition Is Not Yet a Clear Winning Strategy in HR+/HER2- Breast Cancer

May 10th 2021

Conflicting results from the phase 3 monarchE, PENELOPE-B, and PALLAS trials have thrown the role of adjuvant CDK4/6 inhibition into question in patients with high-risk, early-stage hormone receptor–positive, HER2-negative breast cancer.

RxPONDER Trial in HR+ Operable Breast Cancer

May 10th 2021

Priyanka Sharma, MD, and Lajos Pusztai, MD, PhD, review recent results from the RxPONDER trial looking at the predictive value of the Oncotype DX RS on benefit of adjuvant chemotherapy in women with lymph node-positive, HR+, HER2- breast cancer.

HR+ Breast Cancer: Oncotype DX RS and TAILORx

May 10th 2021

Experts in breast cancer provide a historic perspective on the use of the Oncotype DX recurrence score (RS) in patients with HR+, HER- breast cancer and review practical implications from the TAILORx trial.

Dr. de Ligt on Using Symptom Burden to Tailor Follow-Up Care in Breast Cancer Survivors

May 8th 2021

Kelly de Ligt, PhD, discusses subgroups of symptom burden seen in breast cancer survivors.